Company Filing History:
4 out of 24 
4 out of 92 
1 out of 36 
Years Active: 2008-2025
Title: The Innovative Contributions of Ronald Kühne
Introduction
Ronald Kühne is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of chemical compounds, particularly in the development of pharmaceutical agents aimed at treating tumor diseases. With a total of 6 patents to his name, Kühne's work has the potential to impact cancer treatment significantly.
Latest Patents
Kühne's latest patents include "Polyproline mimetics of proline-derived module-15" and "Inhibitors for inhibiting tumor metastasis." The first patent relates to chemical compounds that serve as structural mimetics of proline-rich peptides. These compounds are capable of selectively inhibiting Ena/VASP-EVH1-mediated protein-protein interactions. The invention also discusses the use of these compounds as pharmaceutical agents for treating tumor diseases. The second patent similarly focuses on chemical compounds that inhibit tumor metastasis by affecting the chemotaxis and motility of invasive tumor cells. Both inventions highlight Kühne's commitment to advancing cancer treatment through innovative chemical solutions.
Career Highlights
Throughout his career, Ronald Kühne has worked with notable organizations such as Forschungsverbund Berlin E.V. and Universität zu Köln. His experience in these institutions has allowed him to collaborate with other experts in the field and further his research in chemical compounds and their applications in medicine.
Collaborations
Kühne has collaborated with esteemed colleagues, including Hans-Günther Schmalz and Matthias Müller. These partnerships have contributed to the development of his innovative patents and have fostered a collaborative environment for research and discovery.
Conclusion
Ronald Kühne's contributions to the field of chemical compounds and cancer treatment are noteworthy. His innovative patents and collaborations reflect his dedication to advancing medical science. As he continues to develop new solutions, Kühne remains a significant figure in the realm of pharmaceutical innovation.